

(BW)(CA-DEXCOM) DexCom Inc. Adds New Board Members; Donald L. Lucas Elected as Chairman; Jay S. Skyler Elected as a Director

Business Editors and Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--Oct. 21, 2002--DexCom Inc. today announced the election of two new members to its board of directors: Donald L. Lucas as chairman and Jay S. Skyler, MD, as a director.

Lucas has a long history of assisting small private companies to become successful public enterprises. Lucas has been actively engaged in venture capital activities for more than 40 years and currently serves as chairman of the board of Cadence Design Systems Inc., as chairman of the executive committee of Oracle Corp., as a director of Macromedia Inc., and as a director of PDF Solutions Inc. Lucas is also actively involved in political, educational and community activities. He serves as trustee of the University of Santa Clara, as a director for the American Council for Capital Formation and as chairman of the advisory board for the Stanford Institute for Economic Policy and Research.

Lucas replaces Mark LoGuidice, whose term as the previous chairman for DexCom was successfully completed at the end of September 2002. LoGuidice was largely responsible for building the senior team at DexCom and was involved in successfully raising Series B and Series C financings for DexCom. LoGuidice, who resides in Connecticut, is now focusing full-time on two East Coast ventures in the fields of spine and general surgery.

Skyler is professor of medicine, pediatrics and psychology at the University of Miami in Florida and has been involved in the research and treatment of diabetes for more than three decades. Dr. Skyler has served as president of the American Diabetes Association and as vice president of the International Diabetes Federation. Dr. Skyler served on the board of directors for MiniMed Inc. through its acquisition by Medtronic Inc. in 2001 and is currently on the board of directors for Amylin Pharmaceuticals Inc.

Dr. Skyler replaces John Burd, Ph.D. as a director of DexCom. Dr. Burd was the founding CEO of DexCom Inc. and played a large role in successfully moving DexCom Inc.'s implantable glucose monitor toward commercialization, including successful human feasibility trials. Dr. Burd will return full-time to his previous role in venture capital as a

partner at Windamere Ventures.

DexCom, with headquarters in San Diego, is a private company developing and commercializing the first long-term implantable glucose sensor for people with diabetes.

--30--js/sd* ts/sd

CONTACT: DexCom, San Diego

Andy Rasdal, 858/812-9600, ext. 211

HYPERLINK "mailto:arasdal@dexcominc.com" arasdal@dexcominc.com

KEYWORD: CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL

MANAGEMENT CHANGES

SOURCE: DexCom